In the Trastuzumab for Gastric Cancer (ToGA) trial, treatment with trastuzumab plus CDDP and fluoropyrimidine improved overall survival (OS) compared to chemotherapy alone in patients with advanced gastric or GEJ cancer with HER2 overexpression (13.8 months vs. 11.1 months; p = 0.005) [43]. This evidence concerns the gene ERBB2 and gastric cancer.